China AI drug‑design deals swell as U.S. scrutiny mounts
Riding a wave of booming cross-border dealmaking, China’s AI-driven drug-design firms are charging onto the global stage despite Washington’s growing scrutiny of Chinese biotech firms.
Why it matters: Riding a wave of booming cross-border dealmaking, China’s AI-driven drug-design firms are charging onto the global stage despite Washington’s growing scrutiny of Chinese biotech firms.